Please join us on Thursday, July 26th at noon for a lunch briefing hosted by the Association for Accessible Medicines (AAM) and its Biosimilars Council to learn more about the promise that biosimilars offer to patients and the health care system, and the challenges to the nascent market.
Today, while just 2 percent of the U.S. patient population uses biologics, these products still account for 26 percent of national prescription drug spending–a record $453 billion in 2017, with utilization of these innovative and very costly medicines expected to grow exponentially in the coming years. Biosimilars offer a much-needed alternative, and these advanced treatments are poised to become available at a lower cost to the millions of U.S. patients seeking access to more-affordable versions of biologic medicines to treat their complex and chronic diseases. But whether the promise of biosimilars will be fulfilled for patients is largely dependent on a regulatory, legislative and market landscape for biosimilars that encourages competition and biosimilar development so that America’s patients can benefit from these life-saving therapies.
Join us for in-depth briefing and discussion with representatives from AAM and the Council’s member companies about how the biosimilars industry is working to realize the full potential of biosimilars and ensure that patients have access to these lower-cost medicines. Our members will provide their perspective on a number of issues impacting the emerging biosimilar marketplace, including:
- Biosimilar development & FDA approval process
- Challenges to bringing biosimilars to market
- The EU experience
- Biosimilar education
- Naming & labeling
- Reimbursement issues
|Who:||Patient & Consumer Advocacy, Healthcare Provider, Pharmacist & Health Policy Groups|
|What:||AAM & The Biosimilars Council Lunch Briefing|
|When:||Thursday, July 26th from 12:00 – 1:00 p.m.|
|Where:||AAM Offices601 New Jersey Avenue NW, Suite 850, Washington D.C.|